Alpha 2.0
Login Register
» Authors » Alfons A den Broeder

Alfons A den Broeder

Explore the profile of Alfons A den Broeder including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 151
Citations 3020
Followers 0
Related Specialties
Rheumatology
General Medicine
Pharmacology
Top 10 Co-Authors
Frank H J van den Hoogen
Nathan den Broeder
Aatke van der Maas
Bart J F van den Bemt
Noortje van Herwaarden
Lise M Verhoef
Jaap Fransen
Piet L C M van Riel
Cornelia H M van den Ende
Wietske Kievit
Published In
Rheumatology (Oxford)
Ann Rheum Dis
Clin Exp Rheumatol
J Rheumatol
Trials
Affiliations
Soon will be listed here.
Recent Articles
1.
Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib
Overbeek J, van Erp N, Burger D, den Broeder A, Koolen S, Huitema A, et al.
Clin Pharmacokinet . 2025 Feb; PMID: 39909979
Objectives: Pharmacokinetic (PK) boosting is the intentional use of strong inhibitors of metabolic enzymes or transporters to boost the systemic exposure of a therapeutic drug. PK boosting is expanding to...
2.
Fatigue patterns surrounding biologic disease-modifying antirheumatic drug injection in patients with an inflammatory rheumatic disease: an ecological momentary assessment study
van Lint J, Vriezekolk J, Jessurun N, den Broeder A, van den Bemt B, Huiskes V
Rheumatol Int . 2025 Jan; 45(1):24. PMID: 39797990
This study investigated severity, course and patterns of fatigue surrounding subcutaneous biological disease-modifying antirheumatic drug (bDMARD) injection in inflammatory rheumatic disease (IRD) patients using ecological momentary assessments and investigated self-reported...
3.
Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab
Wientjes M, van Huissteden J, van Herwaarden N, Verhoef L, den Broeder A
Clin Exp Rheumatol . 2024 Jul; 42(11):2215-2220. PMID: 39051162
Objectives: To determine the effects of dose reduction of rituximab (RTX) on rheumatoid arthritis (RA) disease activity in clinical practice. Methods: Retrospective cohort study of RA patients using RTX, in...
4.
Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate-Lowering Therapy During Remission: A Mixed-Methods Study
Peeters I, Veenstra F, Wanten S, Vriezekolk J, van den Ende C, den Broeder A, et al.
Arthritis Care Res (Hoboken) . 2024 Jun; 76(11):1574-1583. PMID: 38924379
Objective: Long-term gout management is based on reducing serum urate by using urate-lowering therapy (ULT). A lifelong treat-to-target approach is advocated, although a ULT (taper to) stop attempt can be...
5.
Effect of using the Simple Erosion Narrowing Score or Sharp/van der Heijde score on the power of rheumatoid arthritis clinical trials to detect differences in radiographic progression
den Broeder N, Bolhuis T, van Herwaarden N, Bergstra S, Bouman C, van den Hoogen F, et al.
Rheumatology (Oxford) . 2024 Jun; 64(3):1464-1468. PMID: 38867707
Objectives: The Simple Erosion Narrowing Score (SENS) is a simplification of the Sharp/van der Heijde score (SHS). Previous studies found SENS and SHS to have very similar measurement properties, but...
6.
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial
den Broeder N, Verhoef L, de Man Y, Kok M, Thurlings R, van der Weele W, et al.
RMD Open . 2024 Apr; 10(2). PMID: 38599654
Background: The REDO trial (REtreatment with Rituximab in RhEmatoid arthritis: Disease Outcome after Dose Optimisation) showed similar disease activity for retreatment with ultralow doses (200 mg and 500 mg per...
7.
Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study
van der Togt C, den Broeder N, Boonstra M, van der Maas A, den Broeder A, van Herwaarden N
Rheumatology (Oxford) . 2024 Feb; 64(2):533-540. PMID: 38346712
Objective: The objective of this study was to investigate the safety and effectiveness of disease activity-guided dose optimization of TNF inhibitors in RA over 10 years. Methods: The study involved...
8.
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial
Mulder M, Vriezekolk J, van Hal T, Nieboer L, den Broeder N, de Jong E, et al.
Lancet Rheumatol . 2024 Jan; 4(4):e252-e261. PMID: 38288921
Background: Conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) are the preferred first-line treatment in patients with psoriatic arthritis, although there is a paucity of evidence for the efficacy of conventional synthetic...
9.
Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study
Schapink L, den Broeder N, den Broeder A, Verhoef L
Rheumatol Int . 2024 Jan; 44(12):2921-2925. PMID: 38286887
To compare the effectiveness of retreatment of rheumatoid arthritis (RA) patients with rituximab (RTX) following the treat-to-target retreatment (TTr) or fixed interval retreatment (FIr) strategy. RA patients starting RTX treatment...
10.
Long-term efficacy of low-dose radiation therapy on symptoms in patients with knee and hand osteoarthritis: follow-up results of two parallel randomised, sham-controlled trials
van den Ende C, Minten M, Leseman-Hoogenboom M, van den Hoogen F, den Broeder A, Mahler E, et al.
Lancet Rheumatol . 2024 Jan; 2(1):e42-e49. PMID: 38258275
Background: Low-dose radiation therapy is commonly used as treatment for benign diseases, including osteoarthritis, in some countries (eg, Germany). We have previously presented our 3-month follow-up results of two randomised...